ENZOLYTICS INC. ENZC overview

INFORMATION ON ENZOLYTICS, INC. BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICER UPDATE ON FORMULATION OF NEW BUSINESS STRATEGY ALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com ) (the "Company") today released resume information on its new board of directors and chief financial officer. The new board of directors consists of Harry Zhabilov, Chairman; Dr. Lachezar Ivanov, and Dr. Gaurav Chandra. Harry Zhabilov - Mr. Zhabilov is Founder, Chief...

ALLEN, TX / ACCESSWIRE / January 16, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com ). Enzolytics, Inc. has partnered with The Khalpey AI Lab to improve organ recovery, longevity, and the science of aging by combining drug development with artificial intelligence. This collaboration is a significant step in the biotechnology industry, aiming to reshape the complex biology of aging and organ regeneration. The partnership aims to use artificial intelligence to decode and...

Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. Progress ALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com /" https://enzolytics.com/ ). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022...

COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com ). Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,000. The combined company is expected to trade on NASDAQ. The entities have begun the...

Start date is expected by the end of 2023 / beginning of 2024. VIRO also offers an update on Diabetic trials and Sagaliam transaction. ALLEN, TX / ACCESSWIRE / September 6, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Virogentics, Inc. ("VIRO"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today that based on the Bulgarian population of HIV-infected individuals that the sample size for the ITV-1...

COLLEGE STATION, TX / ACCESSWIRE / September 5, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today a continued partnership with Khalpey AI Lab ( https://khalpey-ai.com ) and Contenta, Ltd., Estonia, to identify biomarkers for early onset Alzheimer's disease. Such a discovery could lead to early diagnosis and the design of...

COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation Treaty (PCT) application covering its inventions relating to Anti-SARS-CoV-2 Monoclonal Antibodies. The PCT application has now advanced to filing as a U.S. National Stage Application in the U.S. Patent Office and as a formal European Patent Organization (EPO) application. The EPO application makes...

Reports on Business combination agreement progress ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC....